NuVasive reported financial results for the second quarter of 2016, ended on June 30. The financial report is inclusive of results from Ellipse Technologies and Mega Surgical, as both of those acquisitions were completed in the first quarter 2016.
Here are nine notes:
1. The company's total revenue was $236.2 million in the second quarter of 2016, up 16.4 percent from $202.9 million during the same period last year.
2. For the second quarter 2016, GAAP and non-GAAP gross profit was $176.5 million and $183.8 million, respectively.
3. Total GAAP operating expenses were $116.4 million for the second quarter this year, as compared to $128.6 million for the same period in 2015.
4. Non-GAAP operating expenses were $146.4 million for the second quarter of 2016, up from $123.5 million for the second quarter 2015.
5. NuVasive reported a GAAP net income of $30.2 million, or $0.57 per share, for the second quarter 2016.
6. The company reported a non-GAAP net income of $20.6 million, or $0.40 per share for this quarter.
7. NuVasive completed the acquisition of Biotronic NeuroNetwork during the second quarter. It combined the service offerings of Biotronic with its impulse monitoring business to form NuVasive Clinical Services.
8. The company expects its full-year 2016 revenue to total approximately $962 million.
9. NuVasive also anticipates an adjusted EBITDA margin of approximately 25.4 percent for 2016.